World-class expertise.
Leading-edge technologies.
Record-breaking success.
We’re taking medicine to new heights.
At Nimbus, exquisite selectivity is at the core of everything we do. From people to targets to molecules to partners, our meticulous choices enable us to successfully design and develop small molecule medicines capable of improving patients’ lives. And we have a track record to prove it.
Discover our unique approach to target selection, computational drug design, translational medicine, and clinical development.
Explore our highly selective small molecule medicines for oncology, immunology, and metabolic indications.
Nimbus Therapeutics Presents First Preclinical Data on Novel WRN Inhibitor NTX-452 at 36th EORTC-NCI-AACR Symposium
Nimbus Therapeutics to Present First Preclinical Data from Werner Syndrome Helicase Program at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
